News | Spotlight

Press release from Companies

Published: 2019-10-14 15:02:20

Scandion Oncology: Scandion Oncology A/S receives EU-patent for SCO-101

Scandion Oncology A/S (“Scandion Oncology”) today announces that the European Patent Office (“EPO”) has granted the company’s patent application for SCO-101 when combined with chemotherapy. Patent is valid until May 2037.

Scandion Oncology’s patent No. 17726573.3 was submitted on May 17, 2016 and refers to the use of SCO-101 in combination with an anti-cancer drug for the treatment of a variety of cancers. EPO has now approved the patent application and the patent will be issued on November 5th, 2019 and is valid until May 2037.

CEO Nils Brünner comments

“This is a very important milestone that we have reached by having our “mother” patent issued. Without patent protection it would be very difficult to commercialize SCO-101. By having passed this milestone Scandion Oncology is one step closer to commercialize SCO-101”

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 14, 2019. 

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. 

Läs mer hos Cision
Read more about Scandion Oncology